PROTEIN POLYMER TECHNOLOGIES TO PRESENT AT RODMAN & RENSHAW TECHWEST 7TH ANNUAL HEALTHCARE CONFERENCE

 

 

SAN DIEGO, October 31 -- Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI) announced today that Donald Kaplan, Ph.D., President and Chief Operating Officer of PPTI, will present a Company update at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference being held at The New York Palace Hotel in New York on November 7 - 9, 2005. Dr. Kaplan is scheduled to speak on Wednesday, November 9, 2005 at 12:20 p.m. Eastern Time. A live webcast of the presentation can be accessed at http://wsw.com/webcast/rrshq7/ppti.ob/ and through the Company's website at http://www.ppti.com. The presentation will be archived for a limited time.

 

Contacts

Investor Contact: Erin Davis Director of Communications and Investor Relations Protein Polymer Technologies, Inc. (858) 558-6064 x 120 edavis@ppti.com

Media Contact: Bryan deCastro, (631) 495-9177 Carole Boucard, (954) 370-2524 Creative Public Relations

About Protein Polmer Technologies

Protein Polymer Technologies, Inc. is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The company is headquartered in San Diego, California. For additional information about the company, please visit http://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core technology with corresponding issued and pending patents in key international markets.

Safe Harbor

This press release contains forward-looking statements that are based on management’s views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company’s activities include raising adequate capital to continue operations scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company’s 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.